A Phase 1b/2, single-arm, open-label, multi-center study of MP0250 in combination with osimertinib in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) pretreated with osimertinib
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Molecular Partners AG
Start Date
March 27, 2018
End Date
June 9, 2020
Administered By
Duke Cancer Institute
Awarded By
Molecular Partners AG
Start Date
March 27, 2018
End Date
June 9, 2020